Mundipharma, No­var­tis to dis­trib­ute pain medicine in SE Asia

BioSpectrum (Asia) - - Company -

In­ter­na­tional health­care or­ga­ni­za­tions, No­var­tis and Mundipharma, have signed an agree­ment for the mar­ket­ing, sales and dis­tri­bu­tion of well­known pain medicine brands Voltaren (di­clofenac sodium) and Cataflam (di­clofenac potas­sium) in Malaysia, Thai­land, and the Philip­pines. Di­clofenac is a non-steroidal anti-in­flam­ma­tory drug (NSAID) used to re­lieve pain, swelling (in­flam­ma­tion), and joint stiff­ness caused by arthri­tis. It is avail­able as a tablet, in­jectable and liq­uid cap­sule.

Ac­cord­ing to No­var­tis, the com­pany’s com­mit­ment to en­hance health­care providers and in­sti­tu­tions’ ac­cess to ef­fec­tive medicines will be com­ple­mented by Mundipharma’s core strengths in anes­the­sia and sur­gi­cals in South­east Asia. No­var­tis will re­tain all in­ter­na­tional de­vel­op­ment re­spon­si­bil­ity, as well as clin­i­cal de­vel­op­ment ac­tiv­i­ties. The com­pany will also con­tinue to man­u­fac­ture and sup­ply Voltaren and Cataflam for com­mer­cial use.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.